Clinical trial
Protocol CC100B. CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS
NCT03049046 is registered in ClinicalTrials.gov with Chemigen, LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Protocol CC100B. CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS
- Lead sponsor
- Chemigen, LLC
- Phase
- Phase 1
- Overall status
- Unknown status
- Start date
- April 7, 2017
- Completion date
- March 30, 2018
- Enrollment
- 21 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.